T
Taysha Gene Therapies Inc (TSHA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$4.00
-0.06 (-1.48%)
Market Cap: $1.32B
Last updated: Nov 17, 2026 at 4:11 PM ET
Taysha Gene Therapies Inc (TSHA) Valuation Multiples
Taysha Gene Therapies (TSHA) trades at 296.2x sales and 4.6x book value. Its P/B of 4.6x is below its 5-year median of 5.5x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 296.2x |
| Price to book | 4.6x |
| PEG | N/A |
| FCF yield | -8.7% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 4.6x | 5.5x | N/A |
Valuation History
Over the 4 of the 6 year ends shown that have a P/S, its P/S ranged from 10.5x in 2023 to 169.9x in 2025. 2025 was the highest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $5.50 | 169.9x | 7.1x |
| 2024 | $1.73 | 48.0x | 5.0x |
| 2023 | $1.77 | 10.5x | 4.4x |
| 2022 | $2.26 | 50.9x | 134.3x |
| 2021 | $11.65 | N/A | 4.7x |
| 2020 | $26.54 | N/A | 4.0x |
Frequently Asked Questions About TSHA
What is TSHA's price to sales ratio?
Taysha Gene Therapies has a price to sales ratio of 296.2x.
TSHA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors